Kalamazoo, MI-based Metabolic Solutions Development, a developer of drugs to treat Type 2 diabetes, raised another $6.8 million in equity-based financing, according to a July 29 filing with the Securities and Exchange Commission. Twenty-three investors participated in the sale. Most of the financing is being used for expenses related to converting the company to an LLC structure, CEO Stephen Benoit said.
Author: Sarah Schmid Stevenson
Sarah is a former Xconomy editor. Prior to joining Xconomy in 2011, she did communications work for the Michigan Economic Development Corporation and the Michigan House of Representatives. She has also worked as a reporter and copy editor at the Missoula Independent and the Lansing State Journal. She holds a bachelor's degree in Journalism and Native American Studies from the University of Montana and proudly calls Detroit "the most fascinating city I've ever lived in."
View all posts by Sarah Schmid Stevenson
